Fact CheckerSign in

NCT07230990Recruiting

Mechanisms Of Orbitofrontal Stimulation in Depression

Mechanisms Of Orbitofrontal Stimulation in Depression (MOOD)

Source: ClinicalTrials.gov · Last updated 14 May 2026

Brief summary (registry, in English)

The orbitofrontal cortex (OFC), a region involved in emotional regulation, decision making, and reward processing, is a key area linked to antidepressant response. This study tests whether noninvasive stimulation of the OFC using transcranial magnetic stimulation (TMS) can improve depressive symptoms. TMS uses magnetic fields generated by a coil placed next to the scalp to alter brain activity.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
80 (estimated)
First submitted
6 Nov 2025
Start date
15 Apr 2026
Primary completion date
Dec 2030
Lead sponsor
Subha Subramanian
Diseases
Depression
NCT number
NCT07230990

What you commit to

  • Study type: Interventional
  • Planned participants: 80
  • From 15 Apr 2026 to the primary completion date, Dec 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • DSM-5 moderate to severe substance use disorder within the past three months, based on Structured Clinical Interview for DSM-5

Lab values

  • Conditions that might result in increased risks of side effects or complications from rTMS or MRI, including:
    • History of fainting spells of unknown or undetermined etiology that might constitute seizures
    • Diagnosis of epilepsy with the exception of a single seizure of benign etiology (e.g., febrile seizures) in the judgment of a board-certified neurologist
    • Current or past history of a neurological disorder, such as stroke, a progressive neurologic disease, or intracranial brain lesion(s); and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment
    • Any unstable medical condition
    • Any metal in the brain or skull (excluding dental fillings) unless cleared by the responsible covering MD
    • Any devices which could be affected by TMS or MRI such as a pacemaker, medication pump, nerve stimulator, cochlear implant, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD
    • Pregnancy; All female participants will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study. The pregnancy test will be administered by study staff trained to administer point of care pregnancy testing that complies with institutional laboratory policies

Who the study is looking for

  • Age 18-65 years
  • Must be able to read, speak and understand English
  • DSM-5 diagnosis of major depressive disorder, experiencing a moderate to severe depressive episode (Hamilton Depression Rating Scale score greater than or equal to 17 points)
  • Must be judged by study staff to be capable of completing the study procedures
  • Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Beth Israel Deaconess Medical Center
Coordinator of this site? Confirm its status
BostonUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.